Clinical Trial

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

Study acronym: CANOPY-HCH-3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-07; most recent amendment 2026-01-15.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-10-09
Trial Details
NCT Number NCT06455059
Lead Sponsor BioMarin Pharmaceutical
Conditions Hypochondroplasia
Enrollment 80 participants
Start Date 2024-06-17
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-20